TY - JOUR
T1 - Management of paediatric ulcerative colitis, part 1
T2 - Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition
AU - Turner, Dan
AU - Ruemmele, Frank M.
AU - Orlanski-Meyer, Esther
AU - Griffiths, Anne M.
AU - De Carpi, Javier Martin
AU - Bronsky, Jiri
AU - Veres, Gabor
AU - Aloi, Marina
AU - Strisciuglio, Caterina
AU - Braegger, Christian P.
AU - Assa, Amit
AU - Romano, Claudio
AU - Hussey, Séamus
AU - Stanton, Michael
AU - Pakarinen, Mikko
AU - De Ridder, Lissy
AU - Katsanos, Konstantinos
AU - Croft, Nick
AU - Navas-López, Victor
AU - Wilson, David C.
AU - Lawrence, Sally
AU - Russell, Richard K.
N1 - Publisher Copyright:
Copyright © 2018 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition
PY - 2018
Y1 - 2018
N2 - Background: The contemporary management of ambulatory ulcerative colitis (UC) continues to be challenging with 20% of children needing a colectomy within childhood years. We thus aimed to standardize daily treatment of pediatric UC and inflammatory bowel diseases (IBD)-unclassified through detailed recommendations and practice points. Methods: These guidelines are a joint effort of the European Crohn's and Colitis Organization (ECCO) and the Paediatric IBD Porto group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). An extensive literature search with subsequent evidence appraisal using robust methodology was performed before 2 face-to-face meetings. All 40 included recommendations and 86 practice points were endorsed by 43 experts in Paediatric IBD with at least an 88% consensus rate. Results: These guidelines discuss how to optimize the use of mesalamine (including topical), systemic and locally active steroids, thiopurines and, for more severe disease, biologics. The use of other emerging therapies and the role of surgery are also covered. Algorithms are provided to aid therapeutic decision-making based on clinical assessment and the Paediatric UC Activity Index (PUCAI). Advice on contemporary therapeutic targets incorporating the use of calprotectin and the role of therapeutic drug monitoring are presented, as well as other management considerations around pouchitis, extraintestinal manifestations, nutrition, growth, psychology, and transition. A brief section on disease classification using the PIBD-classes criteria and IBD-unclassified is also part of these guidelines. Conclusions: These guidelines provide a guide to clinicians managing children with UC and IBD-unclassified management to provide modern management strategies while maintaining vigilance around appropriate outcomes and safety issues.
AB - Background: The contemporary management of ambulatory ulcerative colitis (UC) continues to be challenging with 20% of children needing a colectomy within childhood years. We thus aimed to standardize daily treatment of pediatric UC and inflammatory bowel diseases (IBD)-unclassified through detailed recommendations and practice points. Methods: These guidelines are a joint effort of the European Crohn's and Colitis Organization (ECCO) and the Paediatric IBD Porto group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). An extensive literature search with subsequent evidence appraisal using robust methodology was performed before 2 face-to-face meetings. All 40 included recommendations and 86 practice points were endorsed by 43 experts in Paediatric IBD with at least an 88% consensus rate. Results: These guidelines discuss how to optimize the use of mesalamine (including topical), systemic and locally active steroids, thiopurines and, for more severe disease, biologics. The use of other emerging therapies and the role of surgery are also covered. Algorithms are provided to aid therapeutic decision-making based on clinical assessment and the Paediatric UC Activity Index (PUCAI). Advice on contemporary therapeutic targets incorporating the use of calprotectin and the role of therapeutic drug monitoring are presented, as well as other management considerations around pouchitis, extraintestinal manifestations, nutrition, growth, psychology, and transition. A brief section on disease classification using the PIBD-classes criteria and IBD-unclassified is also part of these guidelines. Conclusions: These guidelines provide a guide to clinicians managing children with UC and IBD-unclassified management to provide modern management strategies while maintaining vigilance around appropriate outcomes and safety issues.
KW - Anti-TNF
KW - Calprotectin
KW - Children
KW - Guidelines
KW - Inflammatory bowel disease-unclassified
KW - Management
KW - Mesalamine
KW - Monitoring
KW - Pediatric Ulcerative Colitis Activity Index
KW - Pediatrics
KW - Thiopurines
KW - Treatment
KW - Ulcerative colitis
KW - Vedolizumab
UR - http://www.scopus.com/inward/record.url?scp=85052653220&partnerID=8YFLogxK
U2 - 10.1097/MPG.0000000000002035
DO - 10.1097/MPG.0000000000002035
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 30044357
AN - SCOPUS:85052653220
SN - 0277-2116
VL - 67
SP - 257
EP - 291
JO - Journal of Pediatric Gastroenterology and Nutrition
JF - Journal of Pediatric Gastroenterology and Nutrition
IS - 2
ER -